Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414279 | 0.94 | OPRM1 (0.58) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL30797170 | 0.93 | OPRM1 (0.57) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL29577523 | 0.91 | ERAP1 (0.56) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL29577107 | 0.91 | ERAP1 (0.56) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL29619552 | 0.90 | OPRM1 (0.54) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL7048052 | 0.90 | ERAP1 (0.57) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL7936370 | 0.90 | ERAP1 (0.57) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL7048050 | 0.90 | ERAP1 (0.57) | OPRD1OPRM1ERAP1ERAP2LNPEP | |
| SCHEMBL29577130 | 0.88 | LTA4H (0.57) | ERAP1ERAP2 | |
| SCHEMBL29577979 | 0.88 | LTA4H (0.57) | ERAP1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | OPRD1 3688/4885OPRM1 3068/4885CCKAR 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.